Cord blood cells aim to tame deadly transplant complication

NCT ID NCT07576699

Not yet recruiting Disease control Sponsor: Cellenkos, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new treatment called CK0802 for people with severe graft-versus-host disease (GVHD) that does not respond to steroids. GVHD is a serious complication after a bone marrow or stem cell transplant, where donor immune cells attack the patient's body. CK0802 uses immune cells from donated cord blood to try to calm this attack. The study will include 12 participants and will check for safety and whether the disease improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CK0802 (immune cells from donated cord blood)
What this could lead to: If it works, this could offer a new treatment option for people with severe graft-versus-host disease that does not respond to steroids.
What could go wrong: This is a very early, small trial with only 12 participants. The treatment may not work or could cause serious side effects. It is not yet proven safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEROID REFRACTORY GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STEROID REFRACTORY GRAFT VERSUS HOST DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.